Dacomitinib in lung cancer: a “lost generation” EGFR tyrosine-kinase inhibitor from a bygone era?

EGFR tyrosine-kinase inhibitors (TKIs) have now been firmly established as the first-line treatment for non-small-cell lung cancer (NSCLC) patients harboring activating EGFR mutations, based on seven prospective randomized Phase III trials. However, despite significantly improved overall response ra...

Descripción completa

Detalles Bibliográficos
Autores principales: Ou, Sai-Hong Ignatius, Soo, Ross A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4610796/
https://www.ncbi.nlm.nih.gov/pubmed/26508839
http://dx.doi.org/10.2147/DDDT.S52787

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4610796/
https://www.ncbi.nlm.nih.gov/pubmed/26508839
http://dx.doi.org/10.2147/DDDT.S52787

Ejemplares similares